Vanguard Group Inc. lifted its position in Heska Corporation (NASDAQ:HSKA) by 31.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 461,841 shares of the medical research company’s stock after purchasing an additional 111,232 shares during the quarter. Vanguard Group Inc. owned 6.53% of Heska Corporation worth $47,141,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of HSKA. Victory Capital Management Inc. acquired a new position in shares of Heska Corporation in the first quarter valued at $101,000. State of Alaska Department of Revenue acquired a new position in shares of Heska Corporation in the second quarter valued at $127,000. LS Investment Advisors LLC raised its stake in shares of Heska Corporation by 411.2% in the second quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock valued at $130,000 after purchasing an additional 1,028 shares in the last quarter. Municipal Employees Retirement System of Michigan acquired a new position in shares of Heska Corporation in the second quarter valued at $154,000. Finally, PNC Financial Services Group Inc. raised its stake in shares of Heska Corporation by 199.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,484 shares of the medical research company’s stock valued at $155,000 after purchasing an additional 988 shares in the last quarter. Institutional investors and hedge funds own 80.46% of the company’s stock.
Shares of Heska Corporation (NASDAQ:HSKA) opened at $86.74 on Friday. The stock has a market cap of $626.79, a price-to-earnings ratio of 45.41, a price-to-earnings-growth ratio of 2.53 and a beta of 0.83. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.30 and a quick ratio of 1.12.
Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. Heska Corporation had a return on equity of 15.35% and a net margin of 10.67%. The firm had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. During the same period in the prior year, the business posted $0.45 earnings per share. The business’s revenue was down 6.0% compared to the same quarter last year. equities analysts expect that Heska Corporation will post 2.04 EPS for the current fiscal year.
In other Heska Corporation news, CFO John Mcmahon sold 2,608 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the sale, the chief financial officer now directly owns 193 shares in the company, valued at $19,525.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nancy Wisnewski sold 825 shares of the company’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $102.21, for a total value of $84,323.25. Following the completion of the sale, the executive vice president now owns 38,114 shares in the company, valued at $3,895,631.94. The disclosure for this sale can be found here. Corporate insiders own 14.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Vanguard Group Inc. Purchases 111,232 Shares of Heska Corporation (HSKA)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/05/vanguard-group-inc-purchases-111232-shares-of-heska-corporation-hska.html.
A number of research analysts recently commented on HSKA shares. Benchmark Co. restated a “buy” rating and issued a $120.00 target price (up from $106.00) on shares of Heska Corporation in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price for the company in a research note on Friday, August 4th. BidaskClub upgraded Heska Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, August 3rd. Aegis upped their target price on Heska Corporation from $114.50 to $129.50 and gave the company a “buy” rating in a research note on Tuesday, August 1st. Finally, Canaccord Genuity initiated coverage on Heska Corporation in a research note on Thursday, October 5th. They issued a “buy” rating and a $115.00 target price for the company. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $106.25.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corporation (NASDAQ:HSKA).
What are top analysts saying about Heska Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heska Corporation and related companies.